The peptide market is divided into two distinct channels: research chemical vendors selling peptides for "research purposes only," and physician-supervised clinical providers offering prescription or compounded peptides as part of a medical protocol. Understanding the differences is essential for anyone considering a peptide protocol.
Manufacturing Standards
Research chemical peptides are synthesized by contract peptide manufacturers (primarily in China and India) and sold without pharmaceutical manufacturing oversight. Quality varies dramatically — the same compound from different vendors can have purity ranging from 85% to 99%+. There is no mandatory third-party testing, no sterility testing for injectable products, and no regulatory oversight of the manufacturing process. Clinical peptides from licensed compounding pharmacies are manufactured under USP 795 (non-sterile) or USP 797 (sterile injectable) standards, with mandatory environmental monitoring, sterility testing, and third-party purity verification.
Legal Status
Research chemical peptides occupy a legal gray area. They are sold "not for human use" to avoid FDA regulation, but this disclaimer does not make them legal for human use — it simply shifts liability to the buyer. Physician-supervised clinical peptides are legally prescribed and dispensed through licensed pharmacies, with full legal protection for both the provider and patient.
Risk Profile
The primary risks of research chemical peptides are: incorrect compound (wrong sequence or wrong peptide entirely), bacterial contamination (endotoxins are a serious risk in injectable products not manufactured under sterile conditions), incorrect dosing (underdosed products are extremely common), and legal risk. Physician-supervised protocols eliminate all of these risks through pharmaceutical-grade manufacturing, physician oversight, and legal prescription status.